Related Experiment Videos
Kawasaki disease: an update
1Departments of Pediatrics, LSU Health Sciences Center and Children's Hospital, 1542 Tulane Avenue, T8-1, New Orleans, LA 70112, USA. a61543@pol.net
Insights
Kawasaki disease (KD) is an enigmatic illness with an unknown cause, though infectious agents are suspected. Current treatments like aspirin and IVIG improve outcomes, but research is ongoing for non-responsive cases.
Area of Science:
- Pediatrics
- Immunology
- Infectious Diseases
Background:
- Kawasaki disease (KD) was first described over 30 years ago, with diagnostic criteria remaining largely unchanged.
- The etiology of KD is currently unknown, though infectious agents are implicated.
- Coronary artery aneurysms and associated mortality are significant concerns in KD patients.
Purpose of the Study:
- To review the current understanding of Kawasaki disease.
- To discuss advances in KD management, including aspirin and IVIG.
- To highlight areas requiring further research, such as treatment resistance and long-term outcomes.
Main Methods:
- Review of existing literature on Kawasaki disease.
- Analysis of clinical observations and epidemiological data.
- Discussion of current therapeutic strategies and their efficacy.
Main Results:
- Aspirin and intravenous immunoglobulin (IVIG) have significantly reduced coronary artery aneurysms and mortality.
- A subset of KD patients exhibit resistance to IVIG treatment.
- Pulse steroid therapy shows potential benefit for severe, IVIG-resistant KD.
Conclusions:
- While IVIG and aspirin are effective, management of IVIG-resistant KD requires further investigation.
- The role of steroids and other anti-inflammatory agents in KD treatment needs clarification.
- Future research should focus on identifying the cause, optimizing treatment, and predicting long-term outcomes of KD.
Abstract:
Kawasaki disease (KD) was first reported in Japan more than 30 years ago, but the original diagnostic clinical criteria defined by Dr. Kawasaki are still authentic. The cause of KD remains unknown. Several epidemiologic and clinical observations suggest that it is caused by one or multiple infectious agents, each of which can result in the clinical manifestation of the disease. Advances have been made in the management of the disease with the introduction of aspirin and intravenous immunoglobulin (IVIG) that have had a significant impact on lowering the rate of coronary artery aneurysms and death from the disease. Questions remain regarding the management of those patients whose disease does not respond to IVIG. Some patients with severe KD who are resistant to IVIG may benefit from IV pulse steroids therapy. It remains to be seen whether steroid or other anti-inflammatory agents play a role in the management of patients with KD. Further research studies are needed to identify the possible cause, define the treatment, and predict the long-term outcome of this enigmatic disease.